Coeptis Therapeutics Holdings, Inc. announced that it has entered into a definitive agreement with a single healthcare focused investor for the issuance and sale of an aggregate of 2,000,000 shares of its common stock and accompanying class A warrants and class B warrants for the gross proceeds of $2,000,000, before deducting the placement agent's fees and other offering expenses payable by the company on October 24, 2023. The warrants will have an exercise price $1.36 per share and exercise period commencing immediately upon the earlier of shareholder approval or six months from the issuance date, and a term of eighteen months and five and one-half years. The transaction is expected to close on or about October 26, 2023.